Chromium (Picolinate)

What Chromium Actually Is

Trivalent chromium is a trace metal found in broccoli, grape juice, whole grains and brewer's yeast, at microgram quantities. For sixty years it was listed as an essential nutrient on the strength of a rat experiment: animals on a chromium-poor diet developed glucose intolerance that a yeast fraction corrected. That fraction was named "glucose tolerance factor," and chromium supplements were born.

The supplement is almost always chromium picolinate, a chelate chosen for absorption. Doses run from 200 to 1,000 micrograms — a thousandth of the milligram doses used for most compounds on this site, which is why it is cheap and why it is in nearly every "blood sugar formula" on the shelf.

The uncomfortable part of the profile is that the science underneath has been walked back. In 2014 the European Food Safety Authority reviewed the evidence for chromium's essentiality and set no dietary reference value, finding no evidence of a deficiency state in healthy people. A 2017 review of the newer data concluded that chromium "can only be considered pharmacologically active and not an essential element." The US Adequate Intake still exists; it dates from 2001.

The Evidence in Type 2 Diabetes

The trials in diabetes are numerous, small, heterogeneous and, pooled, modestly positive.

Half a percentage point of HbA1c is real but small — roughly a third of what metformin or berberine produce. Two qualifiers from the 2014 analysis matter: the effect was clearer with chromium picolinate above 200 mcg/day, and it was clearer in people with inadequate glycaemic control at baseline. A heterogeneity of 99.8% in the 2020 pooled fasting glucose result means the trials do not agree with each other, and the average hides both nulls and outliers.

That is a C in diabetes: a consistent direction, a small size, and a trial base nobody would call clean.

The Evidence in People Without Diabetes

This is the section that matters for most of the people buying it.

The 2002 meta-analysis found no association between chromium and glucose or insulin concentrations among non-diabetic subjects — 425 healthy or glucose-intolerant participants across the trials that reported adequate data.

The best single trial since is a 16-week double-blind randomised study of 31 non-obese, normoglycaemic adults given chromium picolinate 500 mcg twice daily or placebo, with insulin sensitivity measured by euglycaemic clamp — the reference method. There was no difference between groups (P = 0.83). Worse, participants with the highest serum chromium after supplementation had a decline in insulin sensitivity (β = −0.83, P = 0.01), which body weight, truncal fat and lipids did not explain. The authors advised caution in recommending the supplement.

One trial of 31 people cannot establish harm. It can, alongside the pooled nulls, establish that the case for chromium in metabolically healthy people is D: no benefit demonstrated by the reference method, and a signal in the wrong direction at high serum levels.

What Chromium Has Never Shown

• Any effect on insulin sensitivity in people without diabetes, by clamp or by pooled fasting markers.
• Weight loss or muscle gain. These marketing claims are no longer permitted in the United States because the trials did not support them.
• A hard outcome — diabetes prevention, cardiovascular events, or neuropathy — in anyone.
• Essentiality. The only convincing human deficiency state is a 1977 case report of a woman on more than five years of total parenteral nutrition, whose glucose intolerance and neuropathy reversed with 250 mcg/day of intravenous chromium — a situation no one eating food is in.

Dosing and the Renal Question

At supplemental doses, safety tier A: the 2014 meta-analysis found adverse events no different from placebo. The renal concern is a case-report signal rather than a trial finding — chronic renal failure in a woman after prolonged over-the-counter picolinate use in 1997, and acute tubular necrosis in a 24-year-old man on a multi-ingredient stimulant product containing picolinate in 2006. Neither proves causation; both are why anyone with kidney disease should not treat chromium as free.

Who This Is Reasonable For

Chromium is reasonable as an optional, cheap third layer for someone with established type 2 diabetes whose HbA1c is above target, taken alongside their medication and judged at 12 weeks. It occupies exactly that slot — Layer 3, optional — in The Insulin Sensitivity Protocol.

For someone with prediabetes, PCOS, or a normal HbA1c who wants to "support blood sugar," the honest answer is that magnesium repletion, resistance training and berberine all have better evidence, and chromium has none. It will not hurt at 200 mcg. It will not help either.

Related Research

• The Insulin Sensitivity Stack: Berberine + Inositol + ALA + Chromium
• The Insulin Sensitivity Protocol
• Alpha-Lipoic Acid: Glucose Disposal, Neuropathy and the Trials That Matter
• Berberine vs. Metformin